Ovid Therapeutics (OVID) Total Non-Current Liabilities (2018 - 2022)

Ovid Therapeutics has reported Total Non-Current Liabilities for 5 years, with the latest figure at $26.1 million in Q1 2022.

• For the quarter ending Q1 2022, Total Non-Current Liabilities rose 59.67% year-over-year to $26.1 million; the trailing twelve-month figure through Mar 2022 stood at $26.1 million (up 59.67% YoY), and the FY2021 full-year result was $14.8 million, down 54.18% from the prior year.
• Total Non-Current Liabilities for Q1 2022 stood at $26.1 million, up from $14.8 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $32.3 million in Q4 2020, with the low at $8.8 million in Q4 2018.
• Historically, Total Non-Current Liabilities has averaged $15.2 million across 5 years, with a median of $11.1 million in 2019.
• Annual changes were most pronounced in 2020 — Total Non-Current Liabilities surged 198.46% — and 2021, when it slumped 64.0%.
• Ovid Therapeutics' Total Non-Current Liabilities stood at $8.8 million in 2018, then climbed by 22.34% to $10.8 million in 2019, then soared by 198.46% to $32.3 million in 2020, then sank by 54.18% to $14.8 million in 2021, then jumped by 76.37% to $26.1 million in 2022.
• The last three Total Non-Current Liabilities figures came in at $26.1 million (Q1 2022), $14.8 million (Q4 2021), and $10.1 million (Q3 2021), per Business Quant data.